Nebivolol 5 mg & S-Amlodipine 5 mg Tablets

Therapeutic Class:

Dosage Forms:

Brand Name: BEVOS

How it works?

Nebivolol & S-Amlodipine Tablet is indicated for the treatment of essential hypertension and the treatment of chronic stable angina.

Hypertension and Chronic Stable Angina
Adults: The usual dosage is one Nebivolol & S-Amlodipine tablet 5mg/5mg, with or without food, once a day. The maximum daily dose should not exceed 5mg/10mg once daily.
Elderly: In patients over 65 years of age, the recommended starting dose is one 2.5mg/5mg tablet daily. The dose may be upward titrated to 5mg/10mg if needed or as prescribed by the physician.
Patients with renal Impairment: No dosage adjustment is required in patients with mild to moderate renal impairment. In patients with severe renal impairment (ClCr < 30 mL/min) the recommended starting dose is 2.5mg/5mg once daily. If needed, upward titration should be performed cautiously.
Patients with hepatic disease: In patients with moderate hepatic impairment (Child-Pugh B), the recommended starting dose is 2.5mg/5mg once daily. If needed, the dosage should be upward titrated cautiously. Nebivolol and Amlodipine have not been studied in patients with severe hepatic impairment and therefore the fixed dose combination of Nebivolol plus Amlodipine is not recommended in patients with this condition.
Children and Adolescents: No studies have been conducted in children and adolescents. Therefore, use in children and adolescents is not recommended.
CYP2D6 Polymorphism: Dose adjustments are not necessary for patients who are CYP2D6 poor metabolizers. The clinical effect and safety profile observed in poor metabolizers were similar to those of extensive metabolizers.

dyspnoea, headache, dizziness, paraesthesia, constipation, nausea, diarrhoea.

Anaesthesia: Continuation of beta-blockade reduces the risk of arrhythmias during induction and intubation. Caution should be observed with certain anaesthetics that cause myocardial depression.
Cardiovascular: In general, beta-adrenergic antagonists should not be used in patients with untreated congestive heart failure (CHF). In patients with ischaemic heart disease, treatment with a beta-adrenergic antagonist should be discontinued gradually. Combination of nebivolol with calcium channel antagonists of the verapamil and diltiazem type is generally not recommended.
Metabolic/Endocrinological: Nebivolol does not affect glucose levels in diabetic patients.
Respiratory: In patients with chronic obstructive pulmonary disorders, beta-adrenergic antagonists should be used with caution as airway constriction may be aggravated.
The safety and efficacy of amlodipine in hypertensive crisis has not been established.
Patients with cardiac failure: Patients with heart failure should be treated with caution. Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure.
Patients with hepatic impairment: The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established.
Elderly patients: In the elderly increase of the dosage should take place with.
Patients with renal impairment: Amlodipine may be used in such patients at normal doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment.

Store below 30°C. Protect from light and moisture.
Keep out of reach of children.

3 x 10 Alu/Alu blister pack
Nebivolol 5 mg & S-Amlodipine 5 mg Tablets – BEVOS is available in an Alu/Alu blister of 10 tablets. Such 03 blisters in a unit carton with package insert.

interested? let’s talk.

Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.

F. A. Q

Frequently Asked Questions

Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.

We have below MOQ for:

  1. Tablet, Capsules & Softgel: 200000 Units
  2. Ampoules : 100000 Units
  3. Vials: 10000 Units
  4. Ointment and Cream: 15000 Units
  5. Suppository: 50000 Units
  6. Syrup and Liquid: 10000 Units
  7. Sachets : 50000 Units

We do ready the product within 45-60 days after product artwork confirmation from your side. So, including transit time you can get the product within 90 days maximum, either by Air or Sea route.

A product's “shelf life” generally means the length of time you can expect a product to look and act as expected and to stay safe for use. This length of time varies, depending on the type of product, how it is used, and how it is stored.

Our products come with a minimum of 24 months to a maximum of 36 months of shelf life.

For, Primary packaging we use aluminium foil with 20 to 50 micron size and PVC foil with 350 to 400 micron depending on product characteristics and stability.

For, Secondary packing we do use 300 to 400 GSM FFB Card board.

For, Tertiary packing we do us 7 ply 150 GSM corrugated boxes to prevent the damage during transits.

Yes, we do have available for all dossier documents according to GMP guidelines for the respective country. We do also provide COPP and Free sale certificates (FSC) on demand to customers for special import permit type of commercial orders.